Phase II Studies

News Phase II Studies

• Circassia’s cat allergy treatment shows sustained symptom improvement

  Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® cat all more

• Mesoblast’s Neofuse stem cell product shows positive results in Phase 2 lumbar fusion trial

  Mesoblast Limited announced that its Phase 2 clinical trial for lumbar spinal fusion had met its safety and efficacy endpoints. The results suggest that Mesoblast’s NeoFuse product comprising allogeneic Mesenchymal Precursor Cells (MPCs) is as effective for interbody lumbar fusion as the gold standa more

• CAVATAK Phase II Melanoma Study achieves interim efficacy subgoal

  Viralytics Limited (VLA) in its US-based Phase II melanoma trial of its virotherapy candidate CAVATAKTM has achieved an interim efficacy subgoal of three Objective Responses (OR). This follows a recent review by the independent Data Monitoring Committee (DMC) of the trial. In the Phase II trial prot more

Publications Phase II Studies

• 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

  Trabectedin (Yondelis® [PharmaMar S.A., Madrid, Spain]) is one of the most promising agents tested in the last two decades in patients with anthracycline/ifosfamide-resistant sarcomas and is the first agent highlighting the notion of prolonged tumor control in advanced soft tissue sarcoma. Indeed, t more

• Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic ...

  by Marina Chiara Garassino, Sheila Piva, Nicla La Verde, Ilaria Spagnoletti, Vittorio Iorno, Claudia Carbone, Antonio Febbraro, Anna Bianchi, Annalisa Bramati, Anna Moretti, Monica Ganzinelli, Mirko Marabese, Marta Gentili, Valter Torri, Gabriella Farina Purpose Neuropathic pain is commonly assoc more

• Inhaled dry powder apomorphine (VR040) for ‘off ’ periods in Parkinson's disease: an in‐clinic double‐blind dose ranging study

  Background ‘Off’ periods increase as Parkinson's disease (PD) progresses and the benefits of standard therapy wane. Subcutaneous apomorphine rescues ‘off’ periods, but patient self‐injection and adverse cutaneous effects are sometimes problematic. Methods We assessed safety, tolerability more

Market studies Phase II Studies

• Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012

  Introduction GlobalData’s new report, "Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012" takes a look at rare and niche diseases, which are an area of intense interest in the global biopharmaceutical industry today. The passage of the Orphan Drug Act in the United States in 19 more

• Pierrel S.p.A. (PRL) - Financial and Strategic SWOT Analysis Review

  Pierrel S.p.A. (PRL) - Financial and Strategic SWOT Analysis Review Summary Pierrel S.P.A. (Pierrel) is a publicly held outsourcing company engaged in offering services to the pharmaceutical companies in two areas, namely, Contract Manufacturing of drug products and consultancies and services for more

• GNI, LTD. (2160) - Financial and Strategic SWOT Analysis Review

  GNI, LTD. (GNI) is a publicly traded bio-pharmaceutical company, focused on the discovery and development and manufacturing of therapeutic drug candidates for the treatment of inflammation and cancer. Currently, it is engaged in the production and sale of its product on the market, such as Gu Bang, more

Websites Phase II Studies